AXIM BIOTECHNOLOGIES, INC. (AXIM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-300K 0 300K 600K 900K Q3 '14: 2.5K Q4 '14: 0 Q1 '15: -2.5K Q2 '15: 9.6K Q3 '15: 31.2K Q4 '15: 49.1K Q1 '16: 63.1K Q2 '16: 62.3K Q3 '16: 50.3K Q4 '16: 47.1K Q1 '17: 51.7K Q2 '17: 44.2K Q3 '17: 44.3K Q4 '17: 47.6K Q1 '18: 43.2K Q2 '18: 47.6K Q3 '18: 44.1K Q4 '18: 195.6K Q1 '19: 198.4K Q2 '19: 190.3K Q3 '19: 184K Q4 '19: 816.5K Q1 '20: 799.5K Q2 '20: 799.5K Q3 '20: 799.5K Q4 '20: 0 Q1 '21: 32.6K Q2 '21: 47.5K Q3 '21: 55.7K Q4 '21: 60.5K Q1 '22: 27.8K Q2 '22: 12.9K Q3 '22: 6.1K Q4 '22: 8.9K Q1 '23: 16.3K Q2 '23: 26.2K Q3 '23: 34.5K Q4 '23: 39.8K Q1 '24: 85.3K Q2 '24: 92.9K Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24

Gross Profit TTM

-140K -70K 0 70K 140K 210K Q2 '15: 12.1K Q3 '15: 892 Q4 '15: -1.2K Q1 '16: -2.5K Q2 '16: -15.4K Q3 '16: -8.3K Q4 '16: -107.1K Q1 '17: -126.2K Q2 '17: -123.1K Q3 '17: -110.9K Q4 '17: 4.7K Q1 '18: 37.6K Q2 '18: 41.2K Q3 '18: 36.1K Q4 '18: 187.1K Q1 '19: 187.2K Q2 '19: 186.8K Q3 '19: 183.7K Q4 '19: 0 Q1 '20: -12.7K Q2 '20: -18.1K Q3 '20: -18.1K Q4 '20: 0 Q1 '21: 32.6K Q2 '21: 47.5K Q3 '21: 55.7K Q3 '15 Q3 '16 Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21

Operating Income TTM

-15M -10M -5M 0 5M 10M 15M Q4 '14: -505.7K Q1 '15: -987K Q2 '15: -2.5M Q3 '15: -4.1M Q4 '15: -10M Q1 '16: -10.5M Q2 '16: -9.4M Q3 '16: -9.3M Q4 '16: -3.8M Q1 '17: -3.3M Q2 '17: -3.2M Q3 '17: -2.9M Q4 '17: -3.1M Q1 '18: -4.7M Q2 '18: -5.6M Q3 '18: -5.4M Q4 '18: -5M Q1 '19: -5.3M Q2 '19: -4.5M Q3 '19: -4.1M Q4 '19: -3.9M Q1 '20: -2.3M Q2 '20: -2.4M Q3 '20: -3.2M Q4 '20: -4.9M Q1 '21: -5.1M Q2 '21: -6.6M Q3 '21: -8.6M Q4 '21: -14M Q1 '22: -14.2M Q2 '22: -13.1M Q3 '22: -11.2M Q4 '22: -4.7M Q1 '23: -4.2M Q2 '23: -3.9M Q3 '23: -3.1M Q4 '23: -2.8M Q1 '24: -2.4M Q2 '24: -2.3M Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24

Net Income TTM

-18M -12M -6M 0 6M 12M 18M Q3 '14: -234.1K Q4 '14: -582.9K Q1 '15: -1.1M Q2 '15: -2.6M Q3 '15: -4.2M Q4 '15: -10.1M Q1 '16: -10.5M Q2 '16: -10.9M Q3 '16: -10.9M Q4 '16: -5.8M Q1 '17: -5.4M Q2 '17: -4.1M Q3 '17: -3.9M Q4 '17: -4.2M Q1 '18: -6.4M Q2 '18: -7.5M Q3 '18: -7.2M Q4 '18: -6.8M Q1 '19: -6.3M Q2 '19: -6.5M Q3 '19: -6M Q4 '19: -6.4M Q1 '20: -6.1M Q2 '20: -4.4M Q3 '20: -5.4M Q4 '20: -6.4M Q1 '21: -5.2M Q2 '21: -9M Q3 '21: -10.4M Q4 '21: -16M Q1 '22: -17.3M Q2 '22: -14.7M Q3 '22: -13.4M Q4 '22: -6.2M Q1 '23: -6.9M Q2 '23: -9.4M Q3 '23: -7.1M Q4 '23: -8.1M Q1 '24: -5.6M Q2 '24: -4.1M Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24

Cost of Revenue TTM

0 60K 120K 180K Q4 '16: 154.1K Q1 '17: 153.7K Q2 '17: 167.2K Q3 '17: 155.2K Q4 '17: 42.9K Q1 '18: 5.6K Q2 '18: 6.4K Q3 '18: 8K Q4 '18: 8.5K Q1 '19: 11.2K Q2 '19: 96.5K Q3 '19: 93.4K Q4 '20: 0 Q1 '21: 0 Q1 '17 Q3 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19 Q1 '21

Operating Cash Flow TTM

-6M -4M -2M 0 2M 4M 6M Q3 '14: -54K Q4 '14: -339K Q1 '15: -804.7K Q2 '15: -968.3K Q3 '15: -1.4M Q4 '15: -1.5M Q1 '16: -1.3M Q2 '16: -1.5M Q3 '16: -1.2M Q4 '16: -1.3M Q1 '17: -1.7M Q2 '17: -1.8M Q3 '17: -2.6M Q4 '17: -3.1M Q1 '18: -3.7M Q2 '18: -4.8M Q3 '18: -4.8M Q4 '18: -4.8M Q1 '19: -4.4M Q2 '19: -2.7M Q3 '19: -3.4M Q4 '19: -3.8M Q1 '20: -4.1M Q2 '20: -5M Q3 '20: -4M Q4 '20: -3.2M Q1 '21: -2.7M Q2 '21: -2.6M Q3 '21: -2.3M Q4 '21: -2.5M Q1 '22: -2.6M Q2 '22: -2.7M Q3 '22: -2.5M Q4 '22: -2M Q1 '23: -1.5M Q2 '23: -1.4M Q3 '23: -1.4M Q4 '23: -1M Q1 '24: -1.1M Q2 '24: -759K Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 200M 400M 600M Q1 '11: 20M Q2 '11: 20M Q3 '11: 20.1M Q1 '12: 33M Q2 '12: 33M Q3 '12: 33M Q2 '13: 33M Q3 '13: 33M Q2 '14: 33M Q3 '14: 33M Q2 '22: 154.9M Q3 '22: 171.9M Q2 '23: 226.3M Q3 '23: 478.5M Q2 '11 Q1 '12 Q3 '12 Q3 '13 Q3 '14 Q3 '22 Q3 '23

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q3 '14: 0.00 Q4 '14: -0.01 Q1 '15: -0.03 Q2 '15: -0.07 Q3 '15: -0.11 Q4 '15: -0.27 Q1 '16: -0.27 Q2 '16: -0.28 Q3 '16: -0.31 Q4 '16: -0.16 Q1 '17: -0.15 Q2 '17: -0.11 Q3 '17: -0.07 Q4 '17: -0.08 Q1 '18: -0.12 Q2 '18: -0.14 Q3 '18: -0.13 Q4 '18: -0.12 Q1 '19: -0.11 Q2 '19: -0.11 Q3 '19: -0.10 Q4 '19: -0.10 Q1 '20: -0.09 Q2 '20: -0.06 Q3 '20: -0.07 Q4 '20: -0.07 Q1 '21: -0.05 Q2 '21: -0.08 Q3 '21: -0.09 Q4 '21: 0.11 Q1 '22: 0.11 Q2 '22: 0.13 Q3 '22: 0.15 Q4 '22: -0.04 Q1 '23: -0.04 Q2 '23: -0.05 Q3 '23: -0.04 Q4 '23: -0.05 Q1 '24: -0.03 Q2 '24: -0.02 Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.